SYRE

Spyre Therapeutics Inc

Add to Watchlist

Advanced Chart

15.250

+0.09(0.594%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

15.785

Open

15.110

VWAP

14.99

Vol

291.99K

Mkt Cap

921.11M

Low

14.721

Amount

4.38M

EV/EBITDA(TTM)

Total Shares

60.40M

544.92M

EV/OCF(TTM)

P/S(TTM)

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in creating inflammatory bowel disease (IBD) and other immune-mediated disease products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches. Its pipeline includes investigational extended half-life antibodies targeting a4b7, TL1A, and IL-23. Its pipeline programs include SPY003, SPY004, SPY130, SPY230, SPY002, SPY001, and SPY120. Its advanced product candidate, SPY001, is a fully human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4b7 integrin being developed for the treatment of IBD. Its co-lead program, SPY002, has nominated two fully human mAb candidates designed to bind to tumor necrosis factor-like ligand 1A (TL1A), both of which are in preclinical development for the treatment of IBD. SPY003 is a preclinical-stage program designed to bind to Interleukin 23 (IL-23) and incorporates half-life extending modifications.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

-0.735

+22.5%

-0.836

+3.24%

-0.725

-46.69%

Estimates Revision

The market is revising No Change the revenue expectations for Spyre Therapeutics, Inc. (SYRE) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 2.14%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+5.07%

In Past 3 Month

Stock Price

Go Up

+2.14%

In Past 3 Month

9 Analyst Rating

272.66% Upside

Wall Street analysts forecast SYRE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SYRE is 56.83 USD with a low forecast of 40.00 USD and a high forecast of 71.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

1 Hold

0 Sell

Strong Buy

272.66% Upside

Current: 15.250

Low

40.00

Averages

56.83

High

71.00

272.66% Upside

Current: 15.250

Low

40.00

Averages

56.83

High

71.00

Leerink Partners

Faisal Khurshid

Buy

Initiates

$45

2025-04-08

Reason

Leerink Partners

Faisal Khurshid

Price Target

$45

2025-04-08

Initiates

Buy

Reason

Jones Trading

Debanjana Chatterjee

Hold

Initiates

n/a

2024-12-11

Reason

Jones Trading

Debanjana Chatterjee

Price Target

n/a

2024-12-11

Initiates

Hold

Reason

Baird

Colleen Kusy

Buy

Maintains

$50 → $65

2024-11-13

Reason

Baird

Colleen Kusy

Price Target

$50 → $65

2024-11-13

Maintains

Buy

Reason

Baird raised the firm's price target on Spyre Therapeutics to $65 from $50 and keeps an Outperform rating on the shares. The firm said they posted better-than-expected initial data from SPY001 and thinks the data incrementally de-risks its lead asset and broad pipeline, which could offer best-in-class dosing and potentially improved efficacy in IBD.

Guggenheim

Yatin Suneja

Strong Buy

Maintains

$50 → $65

2024-10-25

Reason

Guggenheim

Yatin Suneja

Price Target

$50 → $65

2024-10-25

Maintains

Strong Buy

Reason

Wedbush

David Nierengarten

Buy

Initiates

$45

2024-09-04

Reason

Wedbush

David Nierengarten

Price Target

$45

2024-09-04

Initiates

Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Spyre Therapeutics Inc (SYRE.O) is -4.73, compared to its 5-year average forward P/E of -4.87. For a more detailed relative valuation and DCF analysis to assess Spyre Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.87

Current PE

-4.73

Overvalued PE

-1.79

Undervalued PE

-7.95

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.07

Current EV/EBITDA

-2.47

Overvalued EV/EBITDA

0.64

Undervalued EV/EBITDA

-4.77

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

165.25

Current PS

0.00

Overvalued PS

548.83

Undervalued PS

-218.33